An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura

References

• Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 Apr 8;137(14):1855–1861.
   PubMed Web of Science ®Google Scholar
• Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–2846.
   PubMed Web of Science ®Google Scholar
• Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor–cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89(9):3097–3103.
   PubMed Web of Science ®Google Scholar
• Hrdinová J, D’Angelo S, Graça NAG, et al., Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Haematologica. 2018;103(7):1099–1109. .
   PubMed Web of Science ®Google Scholar
• Pascual-Izquierdo C, Del Rio-Garma J, de la Rubia J, et al. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: a nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura. J Clin Apher. 2021;36(4):563–573.
   PubMed Web of Science ®Google Scholar
• Miesbach W, Menne J, Bommer M, et al. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet J Rare Dis. 2019;14(1):260.
   PubMed Web of Science ®Google Scholar
• Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60(10):1676–1682.
   PubMed Web of Science ®Google Scholar
• Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819–826.
   PubMed Web of Science ®Google Scholar
• Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3(7):1432–1436.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Bennett CL, Isonishi A, et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One. 2012;7(3):e33029 .
   PubMed Web of Science ®Google Scholar
• Page EE, KremerHovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1(10):590–600.
   PubMed Web of Science ®Google Scholar
• Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and patho- physiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237–45.
   PubMed Web of Science ®Google Scholar
• Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466–471.
   PubMed Web of Science ®Google Scholar
• Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122(12):2023–2029.
   PubMed Web of Science ®Google Scholar
• Zhan H, Streiff MB, King KE, et al. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion. 2010;50(4):868–874.
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500–1511.
   PubMed Web of Science ®Google Scholar
• Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059–41063.
   PubMed Web of Science ®Google Scholar
• Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med. 2015;66(1):211–225.
   PubMedGoogle Scholar
• Roose E, Veyradier A, Vanhoorelbeke K. Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management. Curr Opin Hematol. 2020;27(5):320–326.
   PubMed Web of Science ®Google Scholar
• Muia J, Zhu J, Gupta G, et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A. 2014;111(52):18584–18589.
   PubMed Web of Science ®Google Scholar
• South K, Luken BM, Crawley JT, et al. Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A. 2014;111(52):18578–18583.
   PubMed Web of Science ®Google Scholar
• Pickens B, Mao Y, Li D, et al. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood. 2015;125(21):3326–3334.
   PubMed Web of Science ®Google Scholar
• Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81(1):8–13.
   PubMed Web of Science ®Google Scholar
• Verbij FC, Stokhuijzen E, Kaijen PH, et al. Identification of glycans on plasma-derived ADAMTS13. Blood. 2016 Nov 24;128(21):e51–8.
   PubMed Web of Science ®Google Scholar
• Petri A, Kim HJ, Xu Y, et al. Crystal structure and substrate-induced activation of ADAMTS13. Nat Commun. 2019;10(1):3781.
   PubMedGoogle Scholar
• Choi H, Aboulfatova K, Pownall HJ, et al. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem. 2007;282(49):35604–35611.
   PubMed Web of Science ®Google Scholar
• Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130(10):1181–1188.
   PubMed Web of Science ®Google Scholar
• Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834–839.
   PubMed Web of Science ®Google Scholar
• Burrus TM, Wijdicks EF, Rabinstein AA. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology. 2009;73(1):66–70.
   PubMed Web of Science ®Google Scholar
• Adili R, Holinstat M. Formation and resolution of pial microvascular thrombosis in a mouse model of thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2019;39(9):1817–1830.
   PubMed Web of Science ®Google Scholar
• Casonato A, Steffan A, Pontara E, et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost. 1999;81(2):224–228.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Chen J, López JA. Flow-driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun. 2015;6(1):7858.
   PubMedGoogle Scholar
• JD U Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978;298(24):1350–1352.
   PubMed Web of Science ®Google Scholar
• Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood. 2010;116(12):2005–2010.
   PubMed Web of Science ®Google Scholar
• Van Dorland HA, Taleghani MM, Sakai K, et al. The international hereditary thrombotic thrombocytopenic purpura registry: key findings at enrollment until 2017. Haematologica. 2019;104(10):2107–2115.
   PubMed Web of Science ®Google Scholar
• Thomas MR, de Groot R, Scully MA, et al. Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. E BioMed. 2015;2(8):942–952
   Google Scholar
• Roose E, Schelpe AS, Joly BS, et al. An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2018;16(2):378–388.
   PubMed Web of Science ®Google Scholar
• Fuchs TA, Kremer Hovinga JA, Schatzberg D, et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012;120(6):1157–1164.
   PubMed Web of Science ®Google Scholar
• Alwan F, Vendramin C, Liesner R, et al. Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood. 2019;133(15):1644–1651.
   PubMed Web of Science ®Google Scholar
• Htun KT, Davis AK. Neurological symptoms as the sole presentation of relapsed thrombotic thrombocytopenic purpura without microangiopathic haemolytic anaemia. Thromb Haemost. 2014;112(4):838–840.
   PubMed Web of Science ®Google Scholar
• Idowu M, Reddy P. Atypical thrombotic thrombocytopenic purpura in a middle-aged woman who presented with a recurrent stroke. Am J Hematol. 2013;88(3):237–239.
   PubMed Web of Science ®Google Scholar
• Sánchez-Luceros A, Farías CE, Amaral MM, et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Throm bHaemost. 2004;92(6):1320–1326.
   PubMed Web of Science ®Google Scholar
• Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1(1):33–40.
   PubMed Web of Science ®Google Scholar
• Terrell DR, Motto DG, Kremer Hovinga JA, et al. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion. 2011;51(10):2237–2243.
   PubMed Web of Science ®Google Scholar
• O’Donnell AS, Fazavana J, O’Donnell JS. The von Willebrand factor - ADAMTS-13 axis in malaria. Res Pract Thromb Haemost. 2022;6(1):e12641.
   PubMed Web of Science ®Google Scholar
• Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007;138(4):534–540.
   PubMed Web of Science ®Google Scholar
• Lerolle N, Dunois-Lardé C, Badirou I, et al. von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. J Thromb Haemost. 2009;7(5):843–850.
   PubMed Web of Science ®Google Scholar
• Rodríguez Rodríguez M, Castro Quismondo N, Zafra Torres D, et al. Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. Int J Lab Hematol. 2021;43(4):O1525.
   Web of Science ®Google Scholar
• Upreti H, Kasmani J, Dane K, et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037–1045.
   PubMed Web of Science ®Google Scholar
• Pagliari MT, Cairo A, Boscarino M, et al. Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis. PLoS One. 2021;16(10):e0258675.
   PubMed Web of Science ®Google Scholar
• Sonneveld MA, Franco OH, Ikram MA, et al. Von Willebrand factor, ADAMTS13, and the risk of mortality: the Rotterdam study. Arterioscler Thromb Vasc Biol. 2016;36(12):2446–2451.
   PubMed Web of Science ®Google Scholar
• Tersteeg C, de Maat S, De Meyer SF, et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation. 2014;129(12):1320–1331.
   PubMed Web of Science ®Google Scholar
• Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103(12):4514–4519.
   PubMed Web of Science ®Google Scholar
• Tsai H-M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91(1):1–19.
   PubMed Web of Science ®Google Scholar
• Plaimauer B, Zimmermann K, Völkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100(10):3626–3632.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetec ADAMTS 13 activity. Blood. 2007;109(7):2815–2822.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Mudde GC, Rieger M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009;7(10):1703–1710.
   PubMed Web of Science ®Google Scholar
• Velásquez Pereira LC, Roose E, Graça NAG, et al. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost. 2021;19(2):478–488.
   PubMed Web of Science ®Google Scholar
• Heeb SR, Schaller M, Kremer Hovinga JA. Naturally occurring anti-idiotypic antibodies portray a largely private repertoire in immune-mediated thrombotic thrombocytopenic purpura. J Immunol. 2022;208(11):2497–2507
   PubMed Web of Science ®Google Scholar
• Zheng XL, Wu HM, Shang D, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010;95(9):1555–1562.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–1533.
   PubMed Web of Science ®Google Scholar
• Jestin M, Benhamou Y, Schelpe AS, et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018;132(20):2143–2153.
   PubMed Web of Science ®Google Scholar
• Roose E, Schelpe AS, Tellier E, et al. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood. 2020;136(3):353–361.
   PubMed Web of Science ®Google Scholar
• Blasco M, Guillén-Olmos E, Diaz-Ricart M, et al. Complement mediated endothelial damage in thrombotic microangiopathies. Front Med (Lausanne). 2022;9:811504.
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhang D, Cao W, et al. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood. 2019;134(13):1095–1105.
   PubMed Web of Science ®Google Scholar
• Abou-Ismail MY, Kapoor S, Citla Sridhar D, et al. Thrombotic microangiopathies: an illustrated review. Res Pract Thromb Haemost. 2022;6(3):e12708.
   PubMed Web of Science ®Google Scholar
• Réti M, Farkas P, Csuka D, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(5):791–798.
   PubMed Web of Science ®Google Scholar
• Turner N, Sartain S, Moake J. Ultra large von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes. Hematol Oncol Clin North Am. 2015;29(3):509–524.
   PubMed Web of Science ®Google Scholar
• Wu H, Jay L, Lin S, et al. Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated thrombotic thrombocytopenic purpura. Br J Haematol. 2020;189(1):e18–e20.
   PubMed Web of Science ®Google Scholar
• Feng S, Liang X, Kroll MH, et al. von Willebrand factor is a cofactor in complement regulation. Blood. 2015;125(6):1034–1037.
   PubMed Web of Science ®Google Scholar
• Elhadad S, Chapin J, Copertino D, et al. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021;203(1):96–104.
   PubMed Web of Science ®Google Scholar
• Markiewski MM, Nilsson B, Ekdahl KN, et al. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184–192.
   PubMed Web of Science ®Google Scholar
• Kurosawa S, Stearns-Kurosawa DJ. Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care. 2014;2(1):65.
   PubMedGoogle Scholar
• Chapin J, Weksler B, Magro C, et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 2012;157(6):772–774.
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Fosse E. The complement system in trauma-related and ischemic tissue damage: a brief review. Shock. 1994;2(4):301–310.
   PubMed Web of Science ®Google Scholar
• Gilbert JS, Banek CT, Katz VL, et al. Complement activation in pregnancy: too much of a good thing? Hypertension. 2012;60(5):1114–1116.
   PubMed Web of Science ®Google Scholar
• Bruins P, Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96(10):3542–3548.
   PubMed Web of Science ®Google Scholar
• Baldwin WM, Ota H, Rodriguez ER. Complement in transplant rejection: diagnostic and mechanistic considerations. Springer Semin Immunopathol. 2003;25(2):181–197.
   PubMed Web of Science ®Google Scholar
• Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest. 2017;127(3):780–789.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Haase N, Müller RB, et al. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study. Crit Care. 2015;19(1):191.
   PubMedGoogle Scholar
• Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008;103(5):398–406.
   PubMed Web of Science ®Google Scholar
• Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J. 2019;17(1):10.
   PubMed Web of Science ®Google Scholar
• Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J. 2018;16(1):20.
   PubMedGoogle Scholar
• van den Born BJ, Löwenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29(5):922–927.
   PubMed Web of Science ®Google Scholar
• Bernardo A, Ball C, Nolasco L, et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3(3):562–570.
   PubMed Web of Science ®Google Scholar
• Lush CW, Kvietys PR. Microvascular dysfunction in sepsis. Microcirculation. 2000;7(2):83–101.
   PubMed Web of Science ®Google Scholar
• Ince C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis. Shock. 2016;45(3):259–270.
   PubMed Web of Science ®Google Scholar
• Noris M, Bucchioni S, Galbusera M, et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005;16(5):1177–1183.
   PubMed Web of Science ®Google Scholar
• Fan X, Kremer Hovinga JA, Shirotani-Ikejima H, et al. Genetic varia- tions in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. Int J Hematol. 2016;103(3):283.
   PubMed Web of Science ®Google Scholar
• Feng S, Eyler SJ, Zhang Y, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013;122(8):1487–1493.
   PubMed Web of Science ®Google Scholar
• Al-Tamimi M, Qiao J, Gardiner EE. The utility of platelet activation biomarkers in thrombotic microangiopathies. Platelets. 2022;33(4):503–511.
   PubMed Web of Science ®Google Scholar
• Nazy I, Elliott TD, Arnold DM. Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor. Br J Haematol. 2020;190(4):594–598.
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Heeb SR, Skowronska M, et al. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemost. 2018;16(4):618–629.
   PubMed Web of Science ®Google Scholar
• Gödel P, Fischer J, Scheid C, et al. Familial acquired thrombotic thrombocytopenic purpura in siblings – no immunogenetic link with associated human leucocyte antigens. Eur J Haematol. 2017;98(3):311.
   PubMed Web of Science ®Google Scholar
• Enjeti AK, de Malmanche T, Chapman K, et al. Genomic investigation of inherited thrombotic microangiopathy-aHUS and TTP. Int J Lab Hematol. 2020;42(Suppl 1):33–40.
   PubMedGoogle Scholar
• Sukumar S, Lämmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med. 2021;10(3):536.
   PubMed Web of Science ®Google Scholar
• Kosugi N, Tsurutani Y, Isonishi A, et al. Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor. Intern Med. 2010;49(7):689–693.
   PubMed Web of Science ®Google Scholar
• Franchini M. Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection. Med Hypotheses. 2005;65(6):1128–1131.
   PubMed Web of Science ®Google Scholar
• Talebi T, Fernandez-Castro G, Montero AJ, et al. A case of severe thrombotic thrombocytopenic purpura with concomitant Legionella pneumonia: review of pathogenesis and treatment. Am J Ther. 2011;18(5):e180–5.
   PubMed Web of Science ®Google Scholar
• Yagita M, Uemura M, Nakamura T, et al. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol. 2005;42(3):420–421.
   PubMed Web of Science ®Google Scholar
• Gunther K, Garizio D, Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion. 2007;47(9):1710–1716.
   PubMed Web of Science ®Google Scholar
• Tersteeg C, Verhenne S, Roose E, et al. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies. Expert Rev Hematol. 2016;9(2):209–221.
   PubMed Web of Science ®Google Scholar
• Morgand M, Buffet M, Busson M, et al. High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French thrombotic microangiopathies reference center. Transfusion. 2014;54(2):389–397.
   PubMed Web of Science ®Google Scholar
• Tehrani HA, Darnahal M, Vaezi M, et al. COVID-19 associated thrombotic thrombocytopenic purpura (TTP); A case series and mini-review. Int Immunopharmacol. 2021;93:107397.
   PubMed Web of Science ®Google Scholar
• Mingot-Castellano ME, Butta N, Canaro M, et al. COVID-19 vaccines and autoimmune hematologic disorders. Vaccines (Basel). 2022 Jun 16;10(6):961.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Scully M, Provôt F, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19):2103–2117.
   PubMed Web of Science ®Google Scholar
• French Reference Center for Thrombotic Microangiopathies; Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888–5897.
   PubMed Web of Science ®Google Scholar
• Lattuada A, Rossi E, Calzarossa C, et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88(9):1029–1034.
   PubMed Web of Science ®Google Scholar
• ECLAXIR Study Group; Stepanian A, Cohen-Moatti M, Sanglier T, et al. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol. 2011;31(7):1703–1709.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood. 2021 Mar 11;137(10):1310–1317.
   PubMed Web of Science ®Google Scholar
• Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000;132(10):794–799.
   PubMed Web of Science ®Google Scholar
• Mingot ME, Pascual C, González A, et al. Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. Med Clin (Barc). 2022;158(12):630.e1–14.
   PubMed Web of Science ®Google Scholar
• Balasubramaniyam N, Yandrapalli S, Kolte D, et al. Cardiovascular complications and their association with mortality in patients with thrombotic thrombocytopenic purpura. Am J Med. 2021;134(2):e89–e97.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Cataland S, Scully M, et al. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021;5(8):2137–2141.
   PubMed Web of Science ®Google Scholar
• Pascual MC, Mingot-Castellano ME, Kerguelen Fuentes AE, et al. Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;bloodadvances.2022008028. DOI:10.1182/bloodadvances.2022008028.
   Google Scholar
• Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010;5(4):e10208.
   PubMed Web of Science ®Google Scholar
• Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157–64.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Vesely SK, Cataland SR, et al., ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486–2495. .
   PubMed Web of Science ®Google Scholar
• Liu A, Dhaliwal N, Upreti H, et al. Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion. 2021 Jan;61(1):266–273.
   PubMed Web of Science ®Google Scholar
• Paydary K, Banwell E, Tong J, et al. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Transfusion. 2020;60(9):2047–2057.
   PubMed Web of Science ®Google Scholar
• Zhao N, Zhou L, Hu X, et al., A modified PLASMIC score including the lactate dehydrogenase/the upper limit of normal ratio more accurately identifies Chinese thrombotic thrombocytopenic purpura patients than the original PLASMIC score. J Clin Apheresis. 2020 Apr;35(2):79–85.
   PubMed Web of Science ®Google Scholar
• Burguet L, Taton B, Prezelin-Reydit M, et al. Urine protein/creatinine ratio in thrombotic microangiopathies: a simple test to facilitate thrombotic thrombocytopenic purpura and hemolytic and uremic syndrome diagnosis. J Clin Med. 2022;11(3):648.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Vesely SK, Cataland SR, et al. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2503–2512.
   PubMed Web of Science ®Google Scholar
• Zhu ML, Reeves HM, Maitta RW. Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura. Thromb Res. 2021;198:72–78.
   PubMed Web of Science ®Google Scholar
• Kucukyurt S, Eskazan AE. Assessment and monitoring of patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): strategies to improve outcomes. J Blood Med. 2020 Sep 28;11:319–326. DOI:10.2147/JBM.S205630.
   PubMed Web of Science ®Google Scholar
• George JN. Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion. 2015;55(1):11–13.
   PubMed Web of Science ®Google Scholar
• Ayanambakkam A, Kremer Hovinga JA, Vesely SK, et al. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. Am J Hematol. 2017;92(11):E644–6.
   PubMed Web of Science ®Google Scholar
• Mackie I, Mancini I, Muia J, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hematol. 2020;42(6):685–696.
   PubMed Web of Science ®Google Scholar
• Muia J, Gao W, Haberichter SL, et al. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2013;11(8):1511–1518.
   PubMed Web of Science ®Google Scholar
• Muia J, Zhu J, Greco SC, et al. Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation. Blood. 2019;133(17):1899–1908.
   PubMed Web of Science ®Google Scholar
• Lippi G, Salvagno GL, Adcock DM, et al. Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample. Int J Lab Hematol. 2010;32(1 Pt 2):132–138.
   PubMed Web of Science ®Google Scholar
• Kokame K, Nobe Y, Kokubo Y, et al. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93–100.
   PubMed Web of Science ®Google Scholar
• Mackie I, Langley K, Chitolie A, et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost. 2013;109(3):488–496.
   PubMed Web of Science ®Google Scholar
• Nakashima MO, Zhang X, Rogers HJ, et al. Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test. Int J Lab Hematol. 2016;38(5):550–559.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(4):631–640.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93(2):232–239.
   PubMed Web of Science ®Google Scholar
• Valsecchi C, Mirabet M, Mancini I, et al. Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 Activity. Thromb Haemost. 2019;119(11):1767–1772.
   PubMed Web of Science ®Google Scholar
• Mirabet M, Blanch S, Puig J, et al. Highly sensitive fully automated chemiluminescent immunoassay for rapid quantification of adamts13 activity. Res Pr. 2017;1:1297.
   Google Scholar
• Pascual C, Nieto JM, Fidalgo T, et al. Multicentric evaluation of the new HemosIL Acustar® Acustar ® chemiluminescence ADAMTS13 activity assay. Int J Lab Hematol. 2021;43(3):485–493.
   PubMed Web of Science ®Google Scholar
• White A, Martin R, Sew K, et al. Economic impact of a rapid, on-demand ADAMTS-13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost. 2022;6(4):e12711.
   PubMed Web of Science ®Google Scholar
• Moore GW, Meijer D, Griffiths MR, et al. A multi-center evaluation of TECHNOSCREEN ® ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13. J Thromb Haemost. 2020;18(7):1686–1694.
   PubMed Web of Science ®Google Scholar
• Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–1594.
   PubMed Web of Science ®Google Scholar
• Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and immunomediated diseases. Blood. 2005;106(4):1262–1267.
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Coppo P, Lämmle B, et al. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3(1):17020.
   PubMed Web of Science ®Google Scholar
• Chudhry H, Sholzberg M, Pavenski K. Adamts-13 inhibitor testing is often negative on initial testing. Blood. 2018;132(Supplement 1):5051.
   Google Scholar
• Vendramin C, Thomas M, Westwood JP, et al. Bethesda assay for detecting inhibitory anti-ADAMTS13 antibodies in immune-mediated thrombotic thrombocytopenic purpura. TH Open. 2018;2(3):e329–33.
   PubMedGoogle Scholar
• Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(Suppl 1):283–301.
   PubMedGoogle Scholar
• Kremer Hovinga JA, George JN. Hereditary thrombotic thrombocytopenic purpura. N Engl J Med. 2019;381(17):1653–1662.
   PubMed Web of Science ®Google Scholar
• von Krogh AS, Quist-Paulsen P, Waage A, et al. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. J Thromb Haemost. 2016;14(1):73–82.
   PubMed Web of Science ®Google Scholar
• Scully M, Thomas M, Underwood M, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211–219.
   PubMed Web of Science ®Google Scholar
• Joly BS, Coppo P, Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2019;12(6):383–395.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. ACMG Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–424.
   PubMed Web of Science ®Google Scholar
• Joly BS, Boisseau P, Roose E, et al. ADAMTS13 gene mutations influence ADAMTS13 conformation and disease age-onset in the French cohort of Upshaw-Schulman syndrome. Thromb Haemost. 2018;118(11):1902–1917.
   PubMed Web of Science ®Google Scholar
• Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120(2):440–448.
   PubMed Web of Science ®Google Scholar
• Luken BM, Turenhout EA, Hulstein J, et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2005;93(2):267–274.
   PubMed Web of Science ®Google Scholar
• Page EE, Kremer Hovinga JA, Terrell DR, et al. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2016;128(17):2175–2178.
   PubMed Web of Science ®Google Scholar
• Cobb BA, Kasper D. Coming of age: carbohydrates and immunity. Eur J Immunol. 2005;35(2):352–356.
   PubMed Web of Science ®Google Scholar
• Kurien BT, Hensley K, Bachmann M, et al. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med. 2006;41(4):549–556.
   PubMed Web of Science ®Google Scholar
• Maas C, Hermeling S, Bouma B, et al. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem. 2007;282(4):2229–2236.
   PubMed Web of Science ®Google Scholar
• Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol. 2015;67(1):56–70.
   PubMed Web of Science ®Google Scholar
• Zheng L, Abdelgawwad MS, Zhang D, et al. Histone-induced thrombotic thrombocytopenic purpura in adamts13-/- zebrafish depends on von Willebrand factor. Haematologica. 2020;105105(4):1107–1119.
   Google Scholar